Efficacy and Safety Evaluation of IBI308 in Patients With Extranodal NK/T Cell Lymphoma Patients
Status:
Completed
Trial end date:
2020-02-28
Target enrollment:
Participant gender:
Summary
This is phase II study. Efficacy and safety evaluation of IBI308 in patients with
relapsed/refractory extranodal NK/T cell lymphoma, nasal type: a multicenter, single arm.